We are live on
!
Find out more
Loomis, Sayles & Company Portfolio holdings
AUM
$74.3B
1-Year Est. Return
24.01%
This Fund
S&P 500
This Quarter
Est. Return
+9.81%
1 Year Est. Return
+24.01%
3 Year Est. Return
+109.67%
5 Year Est. Return
+145.58%
10 Year Est. Return
+623.12%
AUM
$79.2B
AUM Growth
+$3.07B
(+4%)
Cap. Flow
-$2.3B
Cap. Flow
% of AUM
-2.9%
Top 10 Holdings %
Top 10 Hldgs %
48.93%
Holding
809
New
117
Increased
205
Reduced
335
Closed
91
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$331M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
+$327M |
| 3 |
NVO
Novo Nordisk
NVO
|
+$319M |
| 4 |
Allison Transmission
ALSN
|
+$195M |
| 5 |
BA.PRA
Boeing Co 6.00% Series A Preferred Stock
BA.PRA
|
+$50M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$853M |
| 2 |
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
|
+$294M |
| 3 |
NVIDIA
NVDA
|
+$266M |
| 4 |
Netflix
NFLX
|
+$190M |
| 5 |
Meta Platforms (Facebook)
META
|
+$175M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.48% |
| 2 | Consumer Discretionary | 18.83% |
| 3 | Communication Services | 18.1% |
| 4 | Healthcare | 11.79% |
| 5 | Financials | 9.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
StepStone Group
STEP
$3.82B
| $37.9M | 0.05% |
653,947
-56,274
| -8% | -$3.49M |
|
152
The Bancorp
TBBK
$2.84B
| $37.7M | 0.05% |
715,952
+180,586
| +34% | +$9.88M |
|
153
The Ensign Group
ENSG
$10.7B
| $37.6M | 0.05% |
283,101
-81,532
| -22% | -$11.8M |
|
154
TD Synnex
SNX
$20.2B
| $37.6M | 0.05% |
320,448
+4,649
| +1% | +$557K |
|
155
BioMarin Pharmaceuticals
BMRN
$12.4B
| $37.5M | 0.05% |
570,428
+240,684
| +73% | +$16.1M |
|
156
Onto Innovation
ONTO
$15.3B
| $37.1M | 0.05% |
222,689
-43,311
| -16% | -$7.91M |
|
157
Ciena
CIEN
$58.4B
| $36.5M | 0.05% |
430,510
-13,417
| -3% | -$963K |
|
158
Elevance Health
ELV
$85.5B
| $36.3M | 0.05% |
98,378
+39,893
| +68% | +$16.7M |
|
159
CRISPR Therapeutics
CRSP
$5.17B
| $35.9M | 0.05% |
910,965
-34,302
| -4% | -$1.62M |
|
160
Kadant
KAI
$3.99B
| $35.1M | 0.04% |
101,621
-29,828
| -23% | -$10.8M |
|
161
Jefferies Financial Group
JEF
$13.1B
| $35M | 0.04% |
446,447
-56,605
| -11% | -$4.07M |
|
162
Casey's General Stores
CASY
$30.9B
| $34.8M | 0.04% |
87,906
-2,745
| -3% | -$1.11M |
|
163
Home BancShares
HOMB
$6.18B
| $34.7M | 0.04% |
1,227,379
+11,354
| +0.9% | +$328K |
|
164
Federal Agricultural Mortgage
AGM
$2.56B
| $34.7M | 0.04% |
176,119
-249
| -0.1% | -$49.4K |
|
165
Rhythm Pharmaceuticals
RYTM
$7.96B
| $34.6M | 0.04% |
618,485
-18,143
| -3% | -$1M |
|
166
CarGurus
CARG
$3.47B
| $34.6M | 0.04% |
946,974
+245,919
| +35% | +$8.44M |
|
167
Noble Corp
NE
$6.51B
| $34.5M | 0.04% |
1,099,791
-41,754
| -4% | -$1.38M |
|
|
CSW
168
CSW Industrials
CSW
$5.71B
| $33.9M | 0.04% |
96,031
+26,189
| +37% | +$10.2M |
|
169
Western Alliance Bancorporation
WAL
$8.87B
| $33.9M | 0.04% |
405,382
+218,219
| +117% | +$19.2M |
|
170
Cadre Holdings
CDRE
$1.41B
| $33.8M | 0.04% |
1,047,097
+106,366
| +11% | +$3.78M |
|
171
Scholar Rock
SRRK
$6.44B
| $33.6M | 0.04% |
+776,665
| New | +$25.3M |
|
172
Freshpet
FRPT
$3.22B
| $33.3M | 0.04% |
225,069
-7,027
| -3% | -$1.02M |
|
173
BWX Technologies
BWXT
$15.6B
| $33.3M | 0.04% |
299,103
-41,823
| -12% | -$5.11M |
|
174
Ambev
ABEV
$46.4B
| $33.1M | 0.04% |
17,875,266
-456,556
| -2% | -$1.01M |
|
175
PAR Technology
PAR
$735M
| $33M | 0.04% |
+454,260
| New | +$31.1M |
|
Similar funds
CBU
BC
Loomis, Sayles & Company's Q4 2024 Portfolio in Review
As of Q4 2024, Loomis, Sayles & Company held 809 positions worth $79.2B, up 4% from $76.2B the previous quarter. Its ten largest holdings account for 49% of the portfolio.
Loomis, Sayles & Company's Q4 2024 filing shows 117 new, 205 increased, 335 reduced and 91 closed positions. Its largest new stake was Boeing Co 6.00% Series A Preferred Stock: 886,790 shares worth $157M. The largest sale was Tesla, an estimated $853M.
By sector, the portfolio is most concentrated in Technology at 27% of assets, down from 28% a quarter earlier, followed by Consumer Discretionary and Communication Services.
- Loomis, Sayles & Company's largest Q4 2024 buy was Boeing Co 6.00% Series A Preferred Stock: 886,790 shares worth $157M.
- Loomis, Sayles & Company added most to Regeneron Pharmaceuticals in Q4 2024, an estimated $331M increase.
- Loomis, Sayles & Company's biggest Q4 2024 reduction was Tesla, cutting an estimated $853M.
- Loomis, Sayles & Company fully exited Medpace in Q4 2024, selling an estimated $68.7M.
- Loomis, Sayles & Company's ten largest holdings make up 49% of its $79.2B portfolio in Q4 2024.
- Loomis, Sayles & Company opened 117 new positions and closed 91 in Q4 2024.
- Loomis, Sayles & Company's portfolio value rose 4% quarter-over-quarter to $79.2B.
Based on Loomis, Sayles & Company's 13F filing for Q4 2024, filed 12 Feb 2025.